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Despite guidelines recommending screening in all patients with
cirrhosis,1 the majority of patients with hepatocellular carcinoma
(HCC) in North America still present at intermediate or advanced
stages when the curative options of liver transplantation (LT),
surgical resection or radiofrequency ablation (RFA) are not pos-
sible. Although these patients have a poor prognosis, this Consen-
sus Statement2 recognizes that such patients may benefit from
palliative therapies including transarterial chemoembolization
(TACE), transarterial radioembolization (TARE) with Yttrium-90
(90Y), external beam radiotherapy (RT), and systemic therapy with
sorafenib. Selection of the appropriate therapy depends not only
on the stage of the tumor (the presence and extent of vascular
invasion, lymph node involvement or distant metastasis) but also
on the underlying hepatic function, and the performance status
of the patient.
The vast majority of HCC in North America occur in the
setting of a cirrhotic liver.1 It is therefore essential to manage these
patients within a multidisciplinary team that recognizes the
importance of the two co-existing diseases, namely the cancer and
the cirrhosis, each with their own risk of mortality. Patients with
Child Pugh (CP) class A cirrhosis and well preserved liver func-
tion may be candidates for any of the above mentioned therapies
depending on the extent of tumor. Conversely, those with
advanced decompensated liver disease (CP class C cirrhosis) are
poor candidates for any therapy, regardless of the stage of their
liver cancer, because they typically survive only a few months
unless they are candidates for LT.1 Patients with CP class B cirrho-
sis have been underrepresented in randomized clinical trials
(RCTs) of sorafenib and TACE,making specific recommendations
for this group of patients more difficult.
TACE has become the standard of care for intermediate stage,
unresectable patients, with large or multinodular HCC who have
no extrahepatic spread and no portal vein thrombosis (PVT).1 It is
important to recognize that the two RCTs which demonstrated a
survival benefit of TACE over best supportive care each enrolled
only 40 subjects in the TACE arms3,4 In these small studies,
approximately one-third of subjects had single tumors and two-
thirds had multinodular HCC, and all subjects had reasonable
liver function with a patent main portal vein.3,4 Subsequent, meta-
analyses of RCTs have confirmed a survival advantage of TACE,5,6
with a median survival of 18  9.5 months.6 However, it is im-
portant not to extrapolate the benefit of TACE to patients with
massive, infiltrating, bilobar tumors. Although a small study has
suggested that TACE can be done safely in patients with PVT,7 the
9.5 month median survival in this series is comparable to the
results of the SHARP study8 which clearly demonstrated a benefit
of sorafenib therapy in subjects with vascular invasion. There is no
standardized technique for performing chemoembolization, and
although TACE is generally well tolerated it can result in liver
failure, especially in those patients with CP class B cirrhosis or
PVT, and on average 2.4% patients may die within 30 days due
to complications of the procedure.6 TACE performed with doxo-
rubicin eluting beads (DEBs) has been shown to result in lower
systemic exposure to chemotherapy.9 A recent multicenter RCT
demonstrated no statistically significant advantage of TACE with
DEBs compared to conventional TACE, although DEBs were
better tolerated in more difficult to treat patients and therefore
resulted in better response rates in the subgroup of patients with
CP class B cirrhosis.10
Outcomes of TARE with 90Y particles for intermediate stage
HCC patients appear to be similar to TACE. A large single centre
experience with TARE reported overall survival of 17.2 months
for CP class A patients and 7.7 months for those with CP class B
cirrhosis.11 The two technologies have not and probably will not
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be compared in a large head-to-head RCT. TARE requires two
angiograms (one to calculate a shunt fraction and one to deliver
the 90Y particles), has higher direct costs associated with the pro-
cedure, but unlike TACE, can be done as an outpatient without the
need for hospitalization. Limited experience has suggested that 90Y
TARE can be safely performed in patients with complete PVT,12
although this needs more confirmation from other groups. Sur-
vival of 10.4 months has been reported in advanced patients with
vascular invasion who receive TARE,11 but RCTs comparing TARE
and sorafenib are needed to determine the role of this technology
in patients with PVT. TACE and TARE have also been used to
downstage HCC or to keep tumors from extending beyond
accepted criteria in patients awaiting transplantation. There are
no RCTs demonstrating a benefit of this strategy, although it
continues to enjoy popularity in some regions with long waiting
times for LT. Recently, significant progress has been made in tech-
niques to safely deliver external beam radiation to liver tumors.
Patients who are not candidates for other therapies may benefit
from external beam photon or proton RT and studies are under-
way examining its role in combination with systemic therapy or
TACE.
The key issues for the management of intermediate stage HCC
include the adequate selection of each modality for individual
patients, lack of RCTs to assess the benefits of these treatments
in patients with PVT, and whether sorafenib or other newer tar-
geted agents can be safely combined with any of these treatments
to improve outcomes. Until more definitive data from RCTs are
available, the clinical practice pattern will continue to be influ-
enced by the expertise of treating physicians and institutions.
The SHARP8 and Asia-Pacific13 studies have clearly established
sorafenib as the new standard treatment for patients with
advanced HCC. Both studies demonstrated nearly an identical
mortality risk reduction for subjects receiving sorafenib compared
to placebo. The patients enrolled in these studies had good per-
formance status and CP class A cirrhosis. Despite the small retro-
spective studies assessing the clinical experience of sorafenib in
patients with CP class B cirrhosis, further study is needed before
sorafenib can be recommended for all patients with CP class B
cirrhosis. Although generally well tolerated, sorafenib does come
with the risk of hand-foot skin reaction, diarrhea, fatigue, and
hypertension.8,13 Perhaps more important than the survival
benefit of sorafenib (10.7 versus 7.9 months) demonstrated in the
SHARP trial,8 is that the study renewed interest in examining the
role of other systemic therapies, particularly molecularly targeted
agents, in HCC. Sorafenib is now being examined in an adjuvant
role to prevent recurrence following curative intent surgery or
RFA and is being examined in combination with TACE, TARE and
RT. For advanced HCC, sorafenib is under investigation in com-
bination with erlotinib or doxorubicin. Furthermore, there are
several phase III studies ongoing evaluating newer agents such
as sunitinib, brivanib, ABT-869 in patients with advanced HCC.
Further development of effective systemic therapies is met with
many challenges. Understanding the mechanism of action of sor-
afenib that mediates the clinical benefits and escape may provide
insights for developing more effective combination strategies.
In addition to angiogenesis, we need to examine agents targeting
other pathways of hepatocarcinogenesis. We should be mindful
about patient resources and try to select the more promising
agents and regimens through vigorous phase II studies before
moving on to phase III trials.
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